Enanta Pharmaceuticals (FRA:9EP) Change In Payables And Accrued Expense : €-5.53 Mil (TTM As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals Change In Payables And Accrued Expense?

Enanta Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was €-1.02 Mil. It means Enanta Pharmaceuticals's Accounts Payable & Accrued Expense declined by €1.02 Mil from Jun. 2024 to Sep. 2024 .

Enanta Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Sep. 2024 was €-5.46 Mil. It means Enanta Pharmaceuticals's Accounts Payable & Accrued Expense declined by €5.46 Mil from Sep. 2023 to Sep. 2024 .

Enanta Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for Enanta Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals Change In Payables And Accrued Expense Chart

Enanta Pharmaceuticals Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-1.91

10.31

-6.17

-3.48

-5.46

Enanta Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-2.85	-1.43	-5.42	2.35	-1.02

Enanta Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.53 Mil.

Enanta Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Enanta Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (FRA:9EP) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

ENTA:USA

Address

4 Kingsbury Avenue, Watertown, MA, USA, 02472

Website

https://www.enanta.com

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals Headlines

No Headlines